Open AccessFeatures of treatment of patients with psoriasis with metabolic syndrome
Author(s) -
В. Р. Хайрутдинов,
В. Р. Хайрутдинов,
А. В. Самцов,
А. В. Самцов
Publication year - 2018
Publication title -
vestnik dermatologii i venerologii
Language(s) - English
Resource type - Journals
eISSN - 2313-6294
pISSN - 0042-4609
DOI - 10.25208/0042-4609-2018-94-4-68-72
Subject(s) - psoriasis , metabolic syndrome , apremilast , medicine , subclinical infection , drug , dermatology , pharmacology , obesity , psoriatic arthritis
The article provides information on the prevalence of metabolic syndrome in patients with psoriasis. The criteria for the diagnosis of metabolic syndrome are presented. The General mechanisms of inflam - mation development in psoriasis and diseases forming the metabolic syndrome are described. Systemic subclinical inflammatory process developing in psoriasis and metabolic syndrome is considered as the main pathogenetic mechanism of their mutual negative influence. The difficulties of treatment of patients with psoriasis with metabolic syndrome are largely associated with the choice of a safe and effective method of treatment. The description of the drug apremilast (OTEZLA®) is a selective inhibitor of the enzyme phosphodiesterase 4, which may be the best drug in the therapy of patients with psoriasis and metabolic syndrome.